These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32839900)

  • 41. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
    Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
    JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study.
    Simons JM; Jacobs JG; Roijers JP; Beek MA; Boonman-de Winter LJM; Rijken AM; Gobardhan PD; Wijsman JH; Tetteroo E; Heijns JB; Yick CY; Luiten EJT
    Breast Cancer Res Treat; 2021 Jan; 185(2):441-451. PubMed ID: 33073303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study.
    Puig CA; Hoskin TL; Day CN; Habermann EB; Boughey JC
    Ann Surg Oncol; 2017 May; 24(5):1242-1250. PubMed ID: 28000076
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer.
    Vila J; Mittendorf EA; Farante G; Bassett RL; Veronesi P; Galimberti V; Peradze N; Stauder MC; Chavez-MacGregor M; Litton JF; Huo L; Kuerer HM; Hunt KK; Caudle AS
    Ann Surg Oncol; 2016 Oct; 23(11):3501-3509. PubMed ID: 27216742
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Axillary response rates to neoadjuvant chemotherapy in breast cancer patients with advanced nodal disease.
    Goel N; Yadegarynia S; Rodgers S; Kelly K; Collier A; Franceschi D; Moller M; Avisar E; Kesmodel SB
    J Surg Oncol; 2021 Jul; 124(1):25-32. PubMed ID: 33852160
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
    Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
    Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States.
    Pariser AC; Sedghi T; Soulos PR; Killelea B; Gross CP; Mougalian SS
    Breast Cancer Res Treat; 2019 Nov; 178(2):419-426. PubMed ID: 31401686
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
    Lips EH; Mukhtar RA; Yau C; de Ronde JJ; Livasy C; Carey LA; Loo CE; Vrancken-Peeters MJ; Sonke GS; Berry DA; Van't Veer LJ; Esserman LJ; Wesseling J; Rodenhuis S; Shelley Hwang E;
    Breast Cancer Res Treat; 2012 Nov; 136(1):35-43. PubMed ID: 22961065
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
    Fowble B; Jairam AK; Wang F; Peled A; Alvarado M; Ewing C; Esserman L; Park C; Lazar A
    Clin Breast Cancer; 2018 Feb; 18(1):e107-e113. PubMed ID: 28830795
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer.
    Kantor O; Wakeman M; Weiss A; Wong S; Laws A; Grossmith S; Mittendorf EA; King TA
    Ann Surg Oncol; 2021 Mar; 28(3):1358-1367. PubMed ID: 32869154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
    Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
    Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Surgical Axillary Staging Before Neoadjuvant Chemotherapy: Who Gets It and Why We Should Avoid It.
    Iles K; Strassle PD; Agala CB; Button J; Downs-Canner S
    Ann Surg Oncol; 2021 Oct; 28(10):5788-5797. PubMed ID: 34379251
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Breast surgery after neoadjuvant systemic therapy.
    Pawloski KR; Barrio AV
    Transl Breast Cancer Res; 2024; 5():13. PubMed ID: 38751679
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of a novel nomogram-based online tool to predict axillary status after neoadjuvant chemotherapy in cN+ breast cancer: A multicentre study on 1,950 patients.
    Corsi F; Albasini S; Sorrentino L; Armatura G; Carolla C; Chiappa C; Combi F; Curcio A; Della Valle A; Ferrari G; Gasparri ML; Gentilini O; Ghilli M; Listorti C; Mancini S; Marinello P; Meani F; Mele S; Pertusati A; Roncella M; Rovera F; Sgarella A; Tazzioli G; Tognali D; Folli S
    Breast; 2021 Dec; 60():131-137. PubMed ID: 34624755
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer.
    Kantor O; Sipsy LM; Yao K; James TA
    Ann Surg Oncol; 2018 May; 25(5):1304-1311. PubMed ID: 29368152
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nodal Pathologic Complete Response Rates in Luminal Breast Cancer Vary by Genomic Risk.
    Boughey JC; Hoskin TL; Day CN; Goetz MP
    Ann Surg Oncol; 2022 Oct; 29(10):6254-6264. PubMed ID: 35876925
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
    Steger GG; Galid A; Gnant M; Mlineritsch B; Lang A; Tausch C; Rudas M; Greil R; Wenzel C; Singer CF; Haid A; Pöstlberger S; Samonigg H; Luschin-Ebengreuth G; Kwasny W; Klug E; Kubista E; Menzel C; Jakesz R;
    J Clin Oncol; 2007 May; 25(15):2012-8. PubMed ID: 17513805
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
    Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
    Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.